TL1A Transgenic Mouse Models for IBD Fibrosis Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are limited in effectively addressing chronic inflammation and fibrosis, with existing treatments often failing to manage severe cases and surgical intervention being common.
Innovation Solution
The development of TL1A transgenic mouse models with constitutive expression in myeloid or lymphoid cells, using tissue-specific promoters, to study the role of TL1A in gut inflammation and fibrosis, and the use of TL1A antibodies to block TL1A-DR3 signaling, which modulates immune responses and reduces inflammation and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for IBD are used, then treatment of mild to moderate inflammation is achieved, but severe cases with fibrosis are not effectively managed
Solution Approach 1:
The patent targets a specific biological parameter (TL1A-DR3 signaling pathway) to change the therapeutic approach. By blocking this specific pathway with antibodies or small molecules, the treatment addresses fibrosis and chronic inflammation that were not effectively managed by previous broad-spectrum therapies, thereby improving reliability for severe cases.
Solution Approach 2:
The patent introduces TL1A blocking antibodies or small molecules as intermediary substances that specifically interfere with the TL1A-DR3 signaling pathway. This intermediary approach allows selective inhibition of the harmful signaling without affecting other immune pathways, effectively managing fibrosis and chronic inflammation while maintaining therapeutic reliability.
2Reliability
If surgical intervention is performed, then severe IBD cases are managed, but it becomes a common outcome rather than a last resort
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (TL1A-DR3 signaling) that drives fibrosis and chronic inflammation. By removing or blocking this specific harmful pathway through molecular therapy, the treatment addresses the root cause of severe disease, potentially preventing the need for surgical intervention and reducing overall treatment complexity.
3Object-affected harmful factors
If TL1A blocking therapy is applied, then inflammation and fibrosis are reduced, but the mechanism of action requires specific molecular targeting
Solution Approach 1:
The patent employs TL1A blocking antibodies or small molecules as intermediary substances that specifically bind to TL1A or DR3, preventing their interaction. This intermediary mechanism achieves reduction of inflammation and fibrosis through selective molecular targeting, balancing therapeutic effectiveness with targeted specificity.
Solution Approach 2:
The patent changes the biological parameter of TL1A-DR3 signaling activity by introducing blocking agents. This parameter change selectively inhibits the harmful inflammatory and fibrotic pathways while sparing other immune functions, effectively reducing inflammation and fibrosis through precise molecular modulation.
Data Source
AI summary
This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBD), such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis.